SANDBOX-&-CO
Sandbox & Co, a London-based group operating a network of learning businesses, today announced that it has acquired award-winning UK-based children’s subscription service, toucanBox, which will sit within its newest division, Sandbox Experiences.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221005005015/en/
Virginie Charles-Dear, Founder and CEO of toucanBox, UK-based children’s subscription service, that is now part of Sandbox & Co.’s rapidly expanding portfolio (Photo: Business Wire)
Inspired by Montessori learning and championing STEAM (science, technology, engineering, art, and maths), the newly acquired toucanBox provides fun educational opportunities for children aged 3 to 8 yrs. Through custom boxes posted through the letterbox, on a subscription or buy it now basis, it delivers craft materials and activities that help develop children’s key skills and support their cognitive and language development, fine motor skills and mental wellbeing.
‘We have been big fans of toucanBox and feel it is a perfect complement to our existing range of hands-on educational tools.’ said Bhav Singh, founder and CEO of Sandbox. ‘Creativity-filled fun learning is at the heart of what we do and I can’t wait to start working together on new experiences that will keep our users delighted and entertained.’
toucanBox will be joining the company’s new division, Sandbox Experiences, that currently includes Brazilian children’s book club, Leiturinha. Drawing on his expertise in growing Leiturinha into the largest kids book subscription service in Brazil, Sandbox Experiences’ lead, Guilherme Martins, will be focusing on rolling out new products across new markets, including in the USA and Europe.
‘Our goal is to deliver fun-filled learning opportunities for children aged 0-12 around the world’, said Guilherme Martins, president at Sandbox Experiences. ‘toucanBox is the perfect extension to our existing offering and I look forward to collaborating with the team on delivering even more engaging educational opportunities to help improve learning worldwide.’
‘toucanBox is all about learning through hands-on, fun activities and we are excited to join forces with Sandbox to accelerate our growth and pursue our mission to unleash children’s creativity’, said Virginie Charles-Dear, Founder and CEO of toucanBox. ‘We’re looking forward to expanding our product range further and reaching even more families in Europe and across the world.’
Sandbox has seen rapid growth over the last 5 years, and its current portfolio now consists of 18 brands with a peak monthly audience of 65M+ kids, families, and teachers. Its award-winning properties include Code Kingdoms, online coding courses for kids, Hopster, preschool learning platform, and Spanish companies Edujoy and Tellmewow. The company has been acquisitive and continues to focus on its buy and build strategy.
For logo and images click HERE
About Sandbox & Co – https://sandboxandco.com
Sandbox & Co is a London-based group operating a network of learning businesses providing an unparalleled ecosystem of edutainment products that reaches over 65 million children, their parents, and teachers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221005005015/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom